MariMed (OTCMKTS:MRMD) Posts Quarterly Earnings Results, Hits Estimates

MariMed (OTCMKTS:MRMD) announced its earnings results on Wednesday. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01), Zacks reports. The firm had revenue of $44.23 million during the quarter, compared to analyst estimates of $41.20 million. MariMed had a negative net margin of 9.13% and a negative return on equity of 10.71%.

MariMed Trading Up 2.8%

OTCMKTS:MRMD opened at $0.07 on Thursday. MariMed has a twelve month low of $0.04 and a twelve month high of $0.16. The company has a quick ratio of 0.34, a current ratio of 0.92 and a debt-to-equity ratio of 1.78. The business has a 50 day moving average price of $0.07 and a two-hundred day moving average price of $0.07.

MariMed Company Profile

MariMed, Inc. is a U.S.-based cannabis company that develops, operates and manages licensed cannabis cultivation, processing and dispensary facilities. The company serves both medical and adult-use markets, where permitted by state law, and focuses on producing and distributing cannabis flower, concentrates, edibles, tinctures and other cannabis-infused products. MariMed markets products under brands that have included Betty’s Eddies, Nature’s Heritage, InHouse and Kalm Fusion. Its products are sold through the company’s retail operations and third-party dispensaries in its operating markets.